Tempo of Nociscan orders accelerated 2.5x for the final 250 scans in comparison with the primary 250 scans
Additional acceleration of scan volumes anticipated as MRIs are activated for the lately accomplished panel of 10 Key Opinion Chief (KOL) surgeons
All business Nociscans so far have been accomplished on Siemens MRI scanners with further acceleration of volumes anticipated as Philips scanners are onboarded
BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of power low again ache, introduced right now that it has accomplished 1,000 business Nociscan exams.
“The milestone by itself is important, however the tempo of our business adoption is essentially the most thrilling side of reaching 1,000 business scans,” said Brent Ness, CEO of Aclarion. “For context, 36% of those 1,000 research had been carried out up to now 12 months, demonstrating the adoption our technique has produced alongside our journey to straightforward of care. As imaging websites proceed to be added and KOLs proceed to achieve entry to Nociscan, we anticipate hitting the two,000 scan milestone in an much more accelerated style.”
“This achievement solidifies Aclarion’s distinct management within the growing subject of augmented intelligence and the renaissance in MR spectroscopy,” said Ryan Bond, Chief Technique Officer at Aclarion. “Nociscan is the primary of its variety, evidence-based SaaS platform that transforms volumes of advanced knowledge into a transparent, streamlined report that effectively communicates individualized biomarker knowledge to assist physicians optimize remedy methods for sufferers affected by power low again ache. This is a crucial business milestone for our doctor clients, their sufferers, and our group.”
266 million individuals worldwide undergo from degenerative spine illness and low again ache1. Standard imaging and diagnostics present useful structural info however battle to determine the supply of the pathogenic ache. Low surgical success charges (41-57%)2,3 particularly for sufferers affected by discogenic power low again ache (DCLP) are an issue. Of all of the illness states, low again and neck ache account for the very best healthcare spending within the US1.
Aclarion’s disruptive innovation, Nociscan, was created all through a decade of improvement. The Aclarion patent portfolio consists of 22 U.S. patents, 17 worldwide patents, 6 pending U.S. patent purposes, and seven pending worldwide patent purposes, together with patents and patent purposes solely licensed from Regents of the College of California.
Nociscan is at the moment obtainable at imaging amenities using choose mannequin Siemens 1.5T and 3T magnetic resonance spectroscopy. For extra info, please contact firstname.lastname@example.org.
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (MRS), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize medical therapies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By means of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
This press launch incorporates forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, similar to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to quite a few uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Trade Fee. Readers are inspired to overview the part titled “Threat Elements” within the Firm’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.
 Ravindra VM, International Backbone Journal (2018) 8(8): 784-794
 Wei J, Music Y, et al. Comparability of synthetic whole disc substitute versus fusion for lumbar disc illness: a meta-analysis of randomized managed trials. Int Orthop. 2013; 37(7):1315-1325
 Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical remedy of power low again ache: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113